Brett Hanscom

机构：Fred Hutch Cancer Center · ORCID：0000-0003-0618-2979

发表论文 106 篇 · 总被引 9641 次 · h-index 34

代表论文

• Evaluation of long‐acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084 (2025 · Journal of the International AIDS Society · 被引 18)
• Delivering integrated strategies from a mobile unit to address the intertwining epidemics of HIV and addiction in people who inject drugs: the HPTN 094 randomized controlled trial protocol (the INTEGRA Study) (2024 · Trials · 被引 14)
• Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial (2024 · The Lancet HIV · 被引 12)
• Safety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in cisgender female adolescents (HPTN 084-01): a single-arm, open-label, phase 2b trial (2025 · The Lancet HIV · 被引 8)
• HIV DNA Levels in Persons Who Acquired HIV in the Setting of Long-Acting Cabotegravir for HIV Prevention: Analysis of Cases from HPTN 083 and 084 (2024 · AIDS Research and Human Retroviruses · 被引 5)
• Estimated impact of long‐acting injectable PrEP in South Africa: a model comparison analysis (2025 · Journal of the International AIDS Society · 被引 4)